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Context: Polycystic ovary syndrome (PCOS) is a heritable, complex genetic disease. Animal models
suggest that androgen exposure at critical developmental stages contributes to disease patho-
genesis. We hypothesized that genetic variation resulting in increased androgen production pro-
duces the phenotypic features of PCOS by programming during critical developmental periods.
Although we have not found evidence for increased in utero androgen levels in cord blood in the
daughters of womenwith PCOS (PCOS-d), target tissue androgen productionmay be amplified by
increased 5-reductase activity analogous to findings in adult affected women. It is possible to
noninvasively test this hypothesis by examining urinary steroid metabolites.
Objective: We performed this study to investigate whether PCOS-d have altered androgen me-
tabolism during early childhood.
Design, Setting, and Participants: Twenty-one PCOS-d, 1–3 years old, and 36 control girls of com-
parable age were studied at an academic medical center.
Main Outcome Measures: Urinary steroid metabolites were measured by gas chromatography/
mass spectrometry. Twenty-four hour steroid excretion rates and precursor to product ratios sug-
gestive of 5-reductase and 11-hydroxysteroid dehydrogenase activities were calculated.
Results:Agedidnotdifferbutweight for lengthZ-scoreswerehigher inPCOS-dcomparedtocontrolgirls
(P  .02). PCOS-d had increased 5-tetrahydrocortisol:tetrahydrocortisol ratios (P  .04), suggesting in-
creased global 5-reductase activity. There was no evidence for differences in 11-hydroxysteroid dehy-
drogenase activity. Steroidmetabolite excretionwas not correlatedwithweight.
Conclusions: Our findings suggest that differences in androgen metabolism are present in early
childhood in PCOS-d. Increased 5-reductase activity could contribute to the development of PCOS
by amplifying target tissue androgen action. (J Clin Endocrinol Metab 101: 2069–2075, 2016)
Polycystic ovary syndrome (PCOS) is a common, highlyheritable disorder with substantial reproductive and
metabolic morbidities (1). Hyperandrogenemia is the car-
dinal reproductive phenotype in adult female first-degree
relatives of women with PCOS (2). Further, hyperandro-
genemia is present in the daughters (PCOS-d) of affected
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women (3). We have found increased circulating testos-
terone (T) levels in PCOS-d as young as age 8 years (4).
Although a number of susceptibility loci for PCOS have
been reproducibly mapped (5, 6), these loci account for
less than 5% of the approximately 70% heritability of
PCOS (7). Epigenetic mechanisms may account for some
of this so-called “missing heritability” that has been ob-
served in PCOS and other complex genetic traits (8). Phe-
nocopies of PCOS can be produced in animal models by
exposure to androgens during gestation (9, 10), neona-
tally (11), or peripubertally (12). Therefore, the PCOS
phenotypemay result from the interactionsof genetic vari-
ation resulting in hyperandrogenemia and the epigenetic
actions of these androgens in utero as well as during crit-
ical postnatal developmental windows.
The source of androgens could be increased glandular
androgen production. However, at birth, most studies
(13, 14) suggest that cord blood androgen levels in
PCOS-d are decreased. It remains possible that target tis-
sue androgen action is amplified by upregulation of 5-
reductase activity resulting in increased production of
DHT from T (15). If such increases in 5-reductase activ-
ity were the result of variation in PCOS susceptibility
genes, target tissue androgen actionwould be enhanced in
affected individuals when T was available.
Alterations in intracellular steroidogenic enzyme activ-
ity could also increase adrenal androgen production. In-
creased 5-reductase or decreased 11-hydroxysteroid
dehydrogenase type 1 (11HSD1) activity would enhance
cortisol metabolism resulting in a compensatory increase
in ACTH secretion and stimulation of adrenal steroido-
genesis (16, 17). Indeed, evidence for increased 5-reduc-
tase and decreased 11HSD1 activity has been found in
adult women with PCOS (16–21). It is possible to non-
invasively assess global androgen metabolism by measur-
ing urinarymetabolites and precursor: product ratios.We
tested the hypothesis that 5-reductase activity is in-
creased in PCOS-d, who are at genetically high risk for
PCOS, by measuring urinary steroid metabolites.
Materials and Methods
Study population
Twenty-one PCOS-d and 36 control girls aged 1 to 3 years
were studied. We chose this age range to ensure that all subjects
were at a similar developmental stage when the mini-puberty of
infancy was completed, but the infants were still in diapers for
ease of urine collection (22). Target sample sizes of 20 cases and
40 controls were calculated for the primary end point, the ratio
of 5-reduced tetrahydrocortisol (5THF) to its 5-reducedme-
tabolite, THF (5THF/THF), ameasure of 5-reductase activity
(17, 23), assuming 80% power and alpha of 0.05 based on the
mean and SD of this ratio in previous studies comparing PCOS
to control women (17, 23). Subjects were recruited by advertise-
ments in local media and on-line, and by contactingwomenwho
have previously participated in our studies of PCOS and control
adult women. PCOS-d had a mother who fulfilled National In-
stitutes of Health criteria for PCOS (hyperandrogenism and
oligo-anovulation with exclusion of other reproductive disor-
ders (1) as confirmed before recruitment by us or by their per-
sonal physician. Themothers of control girls had regularmenses
every 27–35 days and no signs or symptoms of androgen excess
by a validatedquestionnaire (2).All girlswere in goodhealth and
not taking any medications known to alter steroid hormone me-
tabolism. The Institutional Review Boards of the Feinberg
School of Medicine, Northwestern University, and Ann&Rob-
ertH. Lurie Children’sHospital of Chicago approved this study.
Written informed consent was obtained from the parent or legal
guardian of all subjects.
Data collection
Age, height, weight, medical and reproductive histories were
ascertained by validated questionnaires (2) in PCOS and control
mothers. Timed urine samples were obtained in PCOS-d and
control girls through collection of consecutive wet diapers for a
minimum of 10 and maximum of 24 hours. Pediatric growth
records for height and weight were available in 21 PCOS-d and
30 control girls. Weight for length Z score was calculated based
on the US Centers for Disease Control and Prevention 2000
growth charts (24).
Assays
Urinewas extracted fromdiapers as describedpreviously (25)
and urinary steroid metabolites measured by a quantitative gas
chromatography-mass spectrometry (GC-MS) selected ion-
monitoring method (18). Metabolite concentrations were cor-
rected to reflect 24-hour excretion rates by applying the follow-
ing formula: [(metabolite concentration (g/L)  urine volume
(L))/(24/urine collection time (h))]. Substrate-to-product metab-
olite ratios were calculated to reflect the in vivo net activity of
steroidogenic enzymes. Specifically, the ratio of the glucocorti-
coid metabolite 5THF to its 5-reduced metabolite, THF
(5THF/THF),was theprimary ratioused toassess5-reductase
activity because of the low concentrations of androgen andmin-
eralocorticoid metabolites in this age group (Table 2) (26). The
following ratios were used to assess 11-hydroxysteroid dehy-
drogenase type 1 (11-HSD1) activity: (5THF  THF)/tetra-
hydrocortisone (THE), and cortols/cortolones (27). Total corti-
sol productionwas quantified by the sumof cortisolmetabolites:
THF  5THF  cortisol  cortols (26). Total cortisone pro-
ductionwasquantified by the sumcortisonemetabolites: THE
cortisone  cortolones (26). Total glucocorticoid production
was quantified by the sum of total cortisol and total cortisone
production (26). Total androgen production was quantified by
the sum of androsterone (An)  etiocholanolone (Et) (26).
Statistical analysis
Datawere log-transformedwhen necessary to achieve homo-
geneity of variance.Differences between groupswere assessedby
two-tailed unpaired t tests or Mann-Whitney tests, if homo-
geneity of variance was not achieved. Because weight for
length Z score was higher in the PCOS-d, Pearson or Spear-
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man correlation, depending on the normality of the data, was
performed on all endpoints to determine whether there was a
significant correlation with weight for length Z score. Because
there was no correlation of weight for length Z score with any
endpoint, no statistical adjustment for weight was necessary.
Statistical analyses were performed using SAS 9.4 (SAS Insti-
tute, Inc.). Categorical variables were compared by Fisher’s
exact test. Differences were considered to be significant at P
.05. Data are reported as the untransformed mean  SD.
Results
ThePCOSmothershadincreasedbodymassindex(BMI)com-
pared to controlmothers but their age did not differ (Table 1).
Age and ethnicity of the PCOS-d and control girlswere similar
by design (Table 1).Weight for lengthZ score (P .02, Table
1)washigher in thePCOS-d.The lengthof urine collectiondid
not differ between the groups (P .28, Table 1).
Table 2. Urinary Metabolite Excretion, PCOS Daughters and Control Girls
PCOS-d
n  21
Control Girls
n  36 P Value
P Value Correlation
Weight-for-Length Z Score
Cortisol metabolites
THF 44.7  41.3 39.0  30.7 .64 .50
5-THF 115.2  130.6 68.8  48.0 .13 .40
-cortol 11.5  11.0 7.4  5.5 .07 .82
-cortol 24.7  25.9 16.8  14.5 .27 .44
Cortisola 9.4  10.2 6.8  9.1 .14 .87
Cortisone metabolites
THE 192.4  200.6 165.5  132.9 .69 .56
-cortoloneb 40.4  32.6 34.0  28.6 .64 .73
-cortoloneb 37.1  30.2 32.9  24.2 .80 .84
Cortisone 6.2  5.2 5.9  6.2 .51 .85
Androgen metabolites
An 2.9  3.1 2.5  2.8 .42 .45
Et 1.6  1.4 1.6  1.7 .59 .64
Mineralocorticoid metabolites
THDOC 1.7  2.0 1.2  2.0 .06 .47
5-THDOC 2.3  2.2 1.4  1.7 .05 .69
THA 11.1  15.0 8.0  6.5 .49 .35
5-THA 12.9  16.3 7.3  5.6 .08 .25
THB 7.8  11.9 4.5  4.2 .22 .37
5-THB 45.6  74.1 19.8  16.7 .07 .25
All metabolite concentrations reported in g/24 h. The t tests were performed for two-group comparisons and Spearman correlations for
correlation with weight for length Z-scores unless noted otherwise.
Abbreviations: THA, tetrahydro-11-dehydrocorticosterone; THB, tetrahydrocorticosterone; THDOC, tetrahydrodeoxycorticosterone; THF,
tetrahydrocortisol.
a One outlier PCOS-d cortisol result excluded (result 4 SD above mean).
b Nonparametric tests performed for -cortolone and -cortolone because of a failure to achieve homogeneity of variance.
Table 1. Baseline Characteristics
Mothers
PCOS Mothers
n  21
Control Mothers
n  36 P Value
Age, y 32  4 33  3 .77
BMI, kg/m2 31  8 26  7 .01
Daughters
PCOS-d
n  21
Control Girls
n  36
Age, y 1.7  0.6 1.9  0.5 0.45
Weight for length Z-scorea 0.43  1.04 0.29  0.99 .02
Race/ethnicityb 86% White, non-Hispanic, 6% Hispanic,
6% Asian Indian, 3% Asian
76% White, non-Hispanic, 10% Hispanic,
10% Black, non-Hispanic, 5% Asian Indian
.33
Length of urine collection, h 17.8  4.5 16.5  4.7 .28
Data are presented as mean  SD with the exception of the categorical variable of race/ethnicity, where the percentage of subjects included in
each group are noted. P values listed from t tests unless noted otherwise.
a Weight and length data available on 21 PCOS-d and 30 control girls.
b Categorical variables analyzed by Fisher’s exact test.
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Figure 1 depicts the steroidogenic enzyme and uri-
nary steroid metabolites investigated. There were no
differences between the groups in 24-hour excretion of
any of the cortisol metabolites, although there was a
trend toward increased -cortol in PCOS-d (P  .07,
Table 2). Excretion of the cortisone metabolites and
androgen metabolites was also similar (Table 2). Ex-
cretion of the mineralocorticoid me-
tabolites was similar between the
groups, with the exception of 5-tet-
rahydrodeoxycorticosterone, which
was higher in the PCOS-d (P  .05,
Table 2). Finally, excretion of total
cortisol metabolites (211  212
PCOS-d vs 139  99 control girls,
g/24hours,P .16), total cortisone
metabolites (276  264 PCOS-d vs
238  188 control girls, g/24
hours, P .55), total glucocorticoid
metabolites (498  466 PCOS-d vs
377  281 control girls, g/24
hours, P  .30, Figure 2) and total
androgen metabolites (4.5  4.0
PCOS-d vs 4.1  4.3 control girls,
g/24 hours, P  .53, Figure 2) did
not differ between the groups.
PCOS-d had significantly higher
in vivo 5-reductase net activity
compared to control girls based on
the 5THF/THF ratio (2.6  1.1 PCOS-d vs 2.0  0.9
control girls, P  .04, Figure 2), the most reliable mea-
sure of 5-reductase net activity in this age group. The
An/Et ratio (2.1 1.3 PCOS-d vs 1.8 0.9 control girls,
P .59, Figure 2) and other ratios of 5- to 5-reduced
metabolites (Supplemental Table 1) did not differ be-
tween the two groups. The ratios reflective of 11-
HSD1 activity were similar be-
tween the groups: (5THF 
THF)/THE (P  .17) and cortols/
cortolones (P  .33). Weight for
length Z score did not correlate
with 5THF/THF, An/Et,
(5THF  THF)/THE, or
cortols/cortolones.
Discussion
PCOS-d had evidence for increased
global 5-reductase activity analo-
gous to findings in adultwomenwith
PCOS (16, 17, 19–21). 5-reductase
converts testosterone to its more po-
tent 5-reduced metabolite, DHT
(15). Intracellular conversion of tes-
tosterone to DHT is responsible for
androgen actions in most target tis-
sues (15). In women, increased 5-
reductase activity has been associ-
ated with idiopathic hirsutism (28),
Figure 1. Steroidogenesis pathway highlighting steroidogenic enzyme activities and urinary
steroid metabolites. Urinary steroid metabolites are circled and steroidogenic enzymes are
indicated by black boxes. *The 5-reduced metabolites. ALDO, aldosterone; B, corticosterone;
3-HSD, 3-hydroxysteroid dehydrogenase; 11-HSD, 11-hydroxysteroid dehydrogenase; 17-
HSD, 17-hydroxysteroid dehydrogenase; D4, androstenedione; DOC, deoxycorticosterone;
DHEA, dehydroepiandrosterone; 17HP, 17-OHpregnanolone; 18OHB, 18-hydrocxycorticosterone;
17OHP, 17-hydroxyprogesterone; PD, pregnanediol; 5PD, pregnenediol; PREG, pregnenolone;
17PREG, 17-hydroxypregnenolone; PROG, progesterone; PT, pregnanetriol; 5PT, 5-pregnenetriol;
S, 11-deoxycortisol; THA, tetrahydro-11-dehydrocorticosterone; THB, tetrahydrocorticosterone;
THDOC, tetrahydrodeoxycorticosterone; THF, tetrahydrocortisol; THS, tetrahydrodeoxycortisol.
Figure 2. Metabolite ratios reflective of 5-reductase activity and total cortisol and cortisone
metabolite excretion. PCOS-d (black bars) had an increased 5THF/THF ratio compared to control
girls (open bars), reflecting global increases in 5-reductase activity (*P  .04, A). There was no
difference in An/Et, a second ratio indicating 5-reductase activity (P  .59, B). This discrepancy
may be related to the very low concentrations of these androgen metabolites in this young
cohort. There was no significant difference between the groups in total glucocorticoid
metabolites (P  .30, C) or total androgen metabolites (P  .53, D). Data are mean and SEM.
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androgenic alopecia (29), and acne (30). Increased 5-
reductase activity in specific tissues, such as the skin (31)
and ovary (21), has been reported in women with PCOS.
If genetic variation caused increased 5-reductase activity
in androgen target tissues of affected PCOS-d, it would
result in the amplification of peripheral androgen action
by increasing the intracellular production of DHT from T
(32, 33). These findings are consistentwith our hypothesis
that increases in target tissue androgen production play a
role in the development of PCOS.
Increased 5-reductase activity would only be physio-
logically relevant when T was available. Although persis-
tent increases in androgen secretion do not occur until the
time of adrenarche (32), there are earlier developmental
phases in which androgen secretion may be increased in
girls. The fetal adrenal secretes DHEA, an androgen pre-
cursor that may undergo extraglandular metabolism to T
(34). Although less is knownabout fetal ovarian androgen
production, CYP17A1 is strongly expressed in fetal theca
cells starting as early as 33 weeks, suggesting that intra-
uterine ovarian androgen production is possible (35). A
“mini-puberty” of infancy occurs during the first 3–4
months of life during which time the hypothalamic-pitu-
itary-gonadal axis is active, so it is biologically plausible
that ovarian androgen production could be increased dur-
ing this time (22). Following the first year of life, adrenal
and ovarian androgen production remains quiescent until
the time of adrenarche and subsequent puberty (32, 33).
Detailed investigation of gonadal and adrenal steroid
physiology during infancy and early childhood has been
limited because of ethical and practical challenges of per-
forming invasive studies in this age group (36). Analysis of
urinary steroid metabolites provides a valuable means to
noninvasively investigate sex steroid production in young
children (18).
Androgen exposure in utero (9, 10), neonatally (11), or
peripubertally (12) produces phenocopies of PCOS in sev-
eral animal species (37). During gestation, robust placen-
tal aromatase activity likely protects the fetus from expo-
sure to the increased circulating androgen levels in
motherswithPCOS (38).Nevertheless, it remainspossible
that increases in fetal glandular or target tissue androgen
production are present in females at risk for PCOS, such
as thosedaughtersof affectedwomenwho inheritedPCOS
susceptibility genes. No increase in cord blood androgen
levels has been found in PCOS-d in studies using sensitive
and specific testosterone assay methods (13, 14). How-
ever, increases in androgen production earlier in gestation
or enhanced target tissue 5-reductase activity resulting in
local DHT increases could have escaped detection in stud-
ies using cord blood (13, 14). Alternatively, there could be
increases in androgenproductionpostnatally duringother
developmental windows, such as the “mini-puberty” of
infancy (22).
In contrast to adult affected women, only the 5THF/
THF ratio was increased in PCOS-d, whereas the An/Et
ratio did not differ between the groups. However, the ex-
cretion of An and Et was near the limits of detection of the
assay, limiting the utility of this ratio as a measure of 5-
reductase activity in children of this age, in whom andro-
gen generation is physiologically very low (32, 33). In
adultwomenwithPCOS,5-reductasewaspositively cor-
related with body weight (17, 23). Although body weight
was significantly higher in PCOS-d compared to control
girls, there was no correlation of body weight with any
urinary steroid metabolites suggesting weight differences
did not contribute to the differences in 5-reductase ac-
tivity we found in PCOS-d.
Increased hepatic 5-reductase activity may also en-
hance cortisol inactivation and clearance, resulting in a
compensatory increase in ACTH secretion to normalize
circulating cortisol levels, at the expense of increased ad-
renal androgen production (16, 17). The excretion of glu-
cocorticoid metabolites was increased in adult women
with PCOS (16, 17, 23, 39), consistent with ACTH-me-
diated cortisol production. Further, decreased activity of
11-HSD1, which reduces inactive cortisone to cortisol,
has been reported in some (23, 39) but not all (17) studies
of adult affected women. This change may also result
lower cortisol levels and in compensatory increases in
ACTH release (23, 39). In the present study, neither glu-
cocorticoid metabolite excretion nor 11-HSD1 activity
differed in PCOS-d compared to control girls. These find-
ings suggest that increases in zona fasciculata activity are
not important in the early origins of PCOS.
Our study has some potential limitations. First, urinary
steroid metabolite ratios can estimate global enzyme ac-
tivity, butdonot reflect intracellular steroidogenic enzyme
activity in target tissues (28–30). Nevertheless, this non-
invasive approach is a valuable tool for investigation of
alterations in steroid metabolism in infants and young
children. Second, the difference we observed in 5THF/
THF achieved only modest statistical significance (P 
.04, Figure 2). However, this difference was similar in
magnitude todifferences in5-reductase activityobserved
in lean adult womenwith PCOS compared to lean control
women (17, 23). Further, because genetic factors likely
contributed to the alterations in steroidogenesis, these ef-
fects would be diluted because the PCOS-d group con-
tained both genetically affected and unaffected girls.
In conclusion, our findings suggest that increased 5-
reductase activity is present in girls at risk for PCOS in
early childhood. Hence, enzyme expression in target tis-
sues may be primed toward androgen activation in genet-
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ically affected PCOS-d before the onset of increased glan-
dular DHEA secretion during adrenarche (32, 40). These
findings support our hypothesis that genetic variation
leading to hyperandrogenemia, specifically increased tar-
get tissue production of DHT, contributes to the develop-
ment of PCOS through epigenetic actions during critical
developmental windows. Prospective cohort studies are
needed to determine whether those PCOS-d with early
childhood activation of 5-reductase activity ultimately
develop PCOS.
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